(Reuters) - Cigna said on Monday it will remove AbbVie’s blockbuster rheumatoid arthritis drug Humira from some of its lists of preferred drugs for reimbursement in 2025, and recommend less pricey ...

The biosimilars include Hyrimoz and an unbranded version of Humira from Swiss drugmaker Novartis' (NOVN.S), opens new tab Sandoz generics division, as well as German drugmaker Boehringer Ingelheim's ...

Cigna’s pharmacy benefit manager Express Scripts will put “multiple" biosimilar versions of Abbvie’s expensive rheumatoid arthritis drug Humira in the “same position as the brand” on the PBM’s as a ...

A long-awaited moment for consumers arrived last year when patent protection expired on the nation’s most prescribed medicine, AbbVie’s wildly successful — and costly — rheumatoid arthritis drug ...

If you’re one of the millions of Americans taking the prescription medication Humira, get ready to add the word biosimilars to your conversations with your doctor. Starting July 1, alternatives to the ...

The arthritis drug Humira has been a blockbuster seller for more than two decades. Now, some copycats could end Humira's reign. The blockbuster drug Humira has been one of the world's top sellers for ...

AbbVie is one of the largest global Pharmaceuticals, with a market cap of >$265bn. The company's lead asset - all-time best selling immunology drug Humira - finally loses patent protection this year ...

(Reuters) - Drugmaker AbbVie and Icelandic biopharma company Alvotech have settled a legal fight over Alvotech's proposed generic version of AbbVie's blockbuster arthritis drug Humira, according to an ...

Oct 27 (Reuters) - AbbVie ABBV.N on Friday raised its annual profit forecast after beating quarterly earnings estimates, helped by a lower-than-feared drop in sales of its blockbuster arthritis drug, ...

Forbes contributors publish independent expert analyses and insights. Joshua Cohen is a Boston-based writer who covers health policy. In a unique challenge to drug makers, the Dutch Pharmaceutical ...

(Reuters) - UnitedHealth Group said on Tuesday it will remove AbbVie’s blockbuster rheumatoid arthritis drug Humira from some of its lists of preferred drugs for reimbursement as of Jan. 1, 2025, and ...